spacer
spacer

Search 

Drug/nutraceutical targets classed as GO:0002376 - : immune system process

Targets
Structure(s) of protein in PDB   No structures   Protein names shown in purple are human proteins.
Drugs
Target-drug structure(s) in PDB   Drug structure(s) in PDB   No structures.
Go to page:  1  2  3

Alphabetical listing of protein targets and their drugs

  1.  
Adenylosuccinate synthetase isozyme 1 Q8N142/PURA1_HUMAN
  Drugs:  l-aspartic acid.
  2.  
Adenylosuccinate synthetase isozyme 2 P30520/PURA2_HUMAN
  Drugs:  l-aspartic acid.
  3.  
Bone-marrow proteoglycan P13727/PRG2_HUMAN
  Drugs:  sargramostim.
  4.  
Complement C1q subcomponent subunit A P02745/C1QA_HUMAN
  Drugs:  abciximab, bevacizumab, basiliximab, adalimumab, natalizumab, muromonab, alemtuzumab, trastuzumab, daclizumab, etanercept, cetuximab, palivizumab, tositumomab, rituximab, alefacept, gemtuzumab ozogamicin, ibritumomab, efalizumab.
  5.  
Complement C1q subcomponent subunit B P02746/C1QB_HUMAN
  Drugs:  alemtuzumab, alefacept, adalimumab, etanercept, muromonab, palivizumab, abciximab, bevacizumab, tositumomab, trastuzumab, natalizumab, efalizumab, rituximab, ibritumomab, daclizumab, basiliximab, gemtuzumab ozogamicin, cetuximab.
  6.  
Complement C1q subcomponent subunit C P02747/C1QC_HUMAN
  Drugs:  basiliximab, gemtuzumab ozogamicin, alemtuzumab, cetuximab, palivizumab, bevacizumab, etanercept, efalizumab, adalimumab, abciximab, tositumomab, alefacept, trastuzumab, rituximab, muromonab, daclizumab, ibritumomab, natalizumab.
  7.  
Complement C1r subcomponent P00736/C1R_HUMAN
  Drugs:  alemtuzumab, alefacept, etanercept, muromonab, adalimumab, palivizumab, tositumomab, rituximab, daclizumab, gemtuzumab ozogamicin, bevacizumab, cetuximab, natalizumab, abciximab, trastuzumab, basiliximab, ibritumomab, efalizumab.
  8.  
Complement C1s subcomponent P09871/C1S_HUMAN
  Drugs:  gemtuzumab ozogamicin, abciximab, etanercept, trastuzumab, basiliximab, rituximab, muromonab, ibritumomab, adalimumab, cetuximab.
  9.  
Complement C3 P01024/CO3_HUMAN
  Drugs:  intravenous immunoglobulin.
  10.  
Complement C4-A P0C0L4/CO4A_HUMAN
  Drugs:  intravenous immunoglobulin.
  11.  
Complement C4-B P0C0L5/CO4B_HUMAN
  Drugs:  intravenous immunoglobulin.
  12.  
Complement C5 P01031/CO5_HUMAN
  Drugs:  intravenous immunoglobulin, eculizumab.
  13.  
Complement decay-accelerating factor P08174/DAF_HUMAN
  Drugs:  chloramphenicol.
  14.  
HLA class II histocompatibility antigen, DQ beta 1 chain P01920/DQB1_HUMAN
  Drugs:  insulin, porcine.
  15.  
HLA class II histocompatibility antigen, DQ(6) alpha chain P01906/DQA2_HUMAN
  Drugs:  insulin, porcine.
  16.  
HLA class II histocompatibility antigen, DRB1-1 beta chain P04229/2B11_HUMAN
  Drugs:  glatiramer acetate.
  17.  
High affinity immunoglobulin gamma Fc receptor I P12314/FCGR1_HUMAN
  Drugs:  efalizumab, rituximab, bevacizumab, adalimumab, etanercept, methyl aminolevulinate, abciximab, natalizumab, ibritumomab, intravenous immunoglobulin, daclizumab, tositumomab, palivizumab, cetuximab, porfimer, alefacept, trastuzumab, gemtuzumab ozogamicin, muromonab, alemtuzumab, basiliximab.
  18.  
High affinity immunoglobulin gamma Fc receptor IB Q92637/FCGRB_HUMAN
  Drugs:  intravenous immunoglobulin.
  19.  
Intermediate conductance calcium-activated potassium channel protein 4 O15554/KCNN4_HUMAN
  Drugs:  miconazole, quinine, halothane, clotrimazole.
  20.  
Low affinity immunoglobulin gamma Fc region receptor II-a P12318/FCG2A_HUMAN
  Drugs:  abciximab, adalimumab, trastuzumab, basiliximab, muromonab, gemtuzumab ozogamicin, etanercept, alemtuzumab, rituximab, ibritumomab, palivizumab, tositumomab, alefacept, natalizumab, daclizumab, intravenous immunoglobulin, efalizumab, bevacizumab, cetuximab.

  spacer

spacer